Darzalex seeks reimbursement extensions again in KOR
By Whang, byung-woo | translator Alice Kang
24.10.07 05:20:51
가나다라
0
Darzalex’s reimbursement adequacy will be reviewed by the Drug Reimbursement Evaluation Committee on the 10th
Received ‘reimbursement extension adequacy unclear’ decision previously...company will likely highlight the long-term follow-up study results
The 4-drug regimen that contained Darzalex showed over 30 months’ difference compared with the 3-drug regimen in progression-free survival in the CASSIOPEIA trial
With Janssen Korea reapplying to extend the reimbursement of its Darzalex (daratumumab), which it first failed at the Drug Reimbursement Evaluation Committee’s stage, whether the company will succeed in making progress in its discussions this time is gaining attention.
▲Pic of Darzalex
According to industry sources on the 4th, the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee will deliberate on the adequacy of Dazalex's reimbursement on the 10th.
At the center of the discussion is the DVTd regimen (Darzalex+bortezomib+thalidomide+dexamethasone), which is used as a first-line treatment for multiple myeloma in practice.
In the previous revi
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)